BeiGene, Ltd. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone fourth-quarter filing. Amounts below are in U.S. dollars unless otherwise stated.
Business context
BeiGene is a global commercial-stage biotechnology company focused on oncology medicines. Its internally developed approved products include BRUKINSA (zanubrutinib), tislelizumab and pamiparib; it also sells licensed products, principally in China. The company reported more than 8,000 employees, operations in 23 countries and regions, and more than 90 ongoing or planned clinical trials.
Financial performance and liquidity
| Metric | FY2021 | FY2020 |
|---|---|---|
| Total revenue | $1.176 billion | $308.9 million |
| Product revenue, net | $634.0 million | $308.9 million |
| Collaboration revenue | $542.3 million | None reported |
| Cost of sales | $164.9 million | $70.7 million |
| Gross margin on product sales | 74.0% | 77.1% |
| Research and development expense | $1.459 billion | $1.295 billion |
| Selling, general and administrative expense | $990.1 million | $600.2 million |
| Operating loss | $1.439 billion | $1.658 billion |
| Net loss | $1.413 billion | $1.601 billion |
| Operating cash used | $1.299 billion | $1.283 billion |
Product revenue more than doubled, led by BRUKINSA ($218.0 million, up 422.7%) and tislelizumab ($255.1 million, up 56.2%). XGEVA revenue was $46.0 million and BLINCYTO revenue was $12.5 million. VIDAZA revenue fell 34.6% to $19.6 million; ABRAXANE revenue was zero following its China suspension. Gross margin percentage declined, in part because of NRDL-related price reductions and $57.5 million of distributor compensation for inventory sold at pre-NRDL prices.
Collaboration revenue included $484.6 million recognized for the delivered tislelizumab license and know-how transfer to Novartis, plus $53.7 million for R&D services and $4.0 million for ociperlimab access. Thus, the large revenue increase included substantial collaboration revenue, not just product-sales growth. Net loss improved year over year, but the company remained loss-making and operating cash use was roughly flat.
At year-end, cash and cash equivalents were $4.376 billion and short-term investments were $2.242 billion. Total debt was $629.7 million, including $427.6 million classified as short-term and $202.1 million long-term. Current assets were $7.614 billion and current liabilities $1.600 billion. The company raised $3.393 billion net through its December STAR Market offering; the offering proceeds were subject to disclosed use restrictions. Management said existing cash, cash equivalents and short-term investments were expected to fund operating expenses and capital requirements for at least 12 months after issuance of the financial statements.
Material changes and developments
- Total revenue rose $867.4 million year over year, driven by the Novartis tislelizumab collaboration and higher product sales.
- R&D expense increased 12.7%; SG&A increased 65.0%, reflecting expansion of development and global commercial operations. Internal R&D costs rose as activities were brought in-house and staffing grew.
- Cash and cash equivalents increased to $4.376 billion, mainly reflecting the STAR offering, while short-term investments declined to $2.242 billion.
- Capital investment continued: FY2021 property and equipment purchases were $262.9 million. The company purchased a 42-acre New Jersey site for a planned manufacturing and R&D campus; construction was expected to commence in 2022.
- BRUKINSA received additional market approvals, and its U.S. CLL/SLL application was accepted for review with a stated October 22, 2022 target action date. Tislelizumab was approved in China for another NSCLC indication in January 2022.
Outlook, risks and unusual items
- Outlook: The filing provides no numerical revenue or earnings guidance. Management expects continued losses and significant spending on R&D, manufacturing and commercialization. It stated that available liquidity should cover at least 12 months, while also noting that additional funding may be needed to complete all planned development and launches.
- Novartis arrangements: The tislelizumab deal included a $650 million upfront payment and potential regulatory and sales milestones and royalties. The ociperlimab option deal included a $300 million upfront payment received in January 2022, not included in year-end cash, plus potential option, milestone and royalty payments. Milestones and royalties are contingent and should not be treated as assured revenue.
- Pricing and reimbursement: NRDL inclusion supported demand but reduced prices and margins; further negotiations or volume-based procurement could affect sales and profitability. The filing notes that VIDAZA lost a China procurement bid, restricting use in public hospitals and contributing to lower sales.
- ABRAXANE dispute: China suspended sales and use in March 2020 following inspection findings at a BMS contract manufacturer. BeiGene reports no sales since the suspension and no expected future revenue. It disputes BMS’s 2021 termination notice and is pursuing ICC arbitration; BMS counterclaimed approximately $17 million in recall costs. A hearing was scheduled for June 2022.
- Development and supply risks: Clinical outcomes, regulatory approvals, manufacturing capacity, third-party supply, market acceptance and reimbursement remain uncertain. Multiple approvals are conditional or accelerated and require confirmatory evidence.
- Other key risks: The filing highlights substantial ongoing losses, rapid organizational growth, China/U.S. regulatory and political uncertainty, data and human-genetic-resource rules, foreign-exchange restrictions, and potential U.S. trading consequences if the auditor cannot meet PCAOB inspection requirements.
- Audit and controls: The auditor issued unqualified opinions on the financial statements and internal control over financial reporting; management also assessed controls as effective. The auditor identified R&D accrual estimates and allocation of the Novartis tislelizumab transaction price as critical audit matters.
Most important facts for investors to verify
- How much of future revenue growth is attributable to recurring product sales versus upfront collaboration revenue, milestones and royalties.
- Product-level sales growth, especially BRUKINSA and tislelizumab, alongside NRDL price reductions, channel inventory compensation and gross-margin trends.
- Cash burn, debt maturities and the timing and cost of the New Jersey and China manufacturing expansions, including restricted use of STAR offering proceeds.
- Clinical and regulatory progress, including confirmatory trials required for conditional or accelerated approvals and the stated 2022 filing milestones.
- Developments and potential financial effects of the ABRAXANE arbitration and BMS counterclaim.
- Whether regulatory, audit-inspection and cross-border data risks affecting China-based operations or U.S. securities trading change materially.